Exportación Completada — 

Dislipidemia e índice de masa corporal elevado como factores de riesgo para hiperplasia benigna de próstata

Descripción del Articulo

Introduction: Benign prostatic hyperplasia (BPH) is the most frequent urological disease in men. Despite its generalized prevalence, the etiology is not well understood. Obesity is involved in BPH due to its relationship with metabolic and endocrine changes. There is little information on the role o...

Descripción completa

Detalles Bibliográficos
Autor: Simón Cruz, David
Formato: tesis de grado
Fecha de Publicación:2020
Institución:Universidad Nacional de Trujillo
Repositorio:UNITRU-Tesis
Lenguaje:español
OAI Identifier:oai:dspace.unitru.edu.pe:20.500.14414/15629
Enlace del recurso:https://hdl.handle.net/20.500.14414/15629
Nivel de acceso:acceso abierto
Materia:Hiperplasia Benigna de Próstata
Índice de Masa Corporal
Dislipidemia
Descripción
Sumario:Introduction: Benign prostatic hyperplasia (BPH) is the most frequent urological disease in men. Despite its generalized prevalence, the etiology is not well understood. Obesity is involved in BPH due to its relationship with metabolic and endocrine changes. There is little information on the role of lipids in prostate growth so there is a need for further research in this area. Objective: To determine if dyslipidemia and high body mass index are risk factors for the development of benign prostatic hyperplasia. Material and Method: An observational, case and control study was conducted. A population of 299 patients  40 years was taken into account, of which 159 patients were randomly selected and divided into 53 for the cases and 106 for the controls. Results: It was found that there was no association between high BMI and BPH (χ²: 0.347, OR: 0.813, IC: 0.409 – 1.617, p  0.555). There was no association between dyslipidemia and BPH ((χ²: 3.389, OR: 2.22, IC: 0.937 – 5.261, p  0.066). There was no association between CT, TG, LDL and HDL independently with BPH. Conclusion: The BMI  25 kg/m2 is not a risk factor to develop HBP, in the same way neither the dyslipidemia nor any of its components are risk factors for HBP.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).